Finta

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finta

What is Finta? Defining the Androgen Modulator

Property Description
Active ingredient Finasteride
Form Oral Tablet
Pharmacological class 5-alpha Reductase Inhibitor
General purpose Androgen Modulator (to suppress DHT effects)
Target Patient Group Adult Males
Regulatory Status Prescription-Only Medication (Rx)

What Type of Medication is Finta (Finasteride)?

Finta is a prescription-only synthetic medication that belongs to the pharmacological class of 5-alpha Reductase Inhibitors. It is supplied as a single-ingredient product in a solid, oral tablet form, intended for systemic use after ingestion. The core chemical compound is Finasteride, which is structurally a derivative of the 4-Azasteroid chemical family. Finasteride is clinically recognized for its high specificity as an Enzyme Inhibitor. This focused approach is a distinctive feature of the synthetic 4-Azasteroid structure, contrasting it with medications intended for generalized hormone replacement.

How Does Finta Function at a High Level?

The general purpose of Finta is to achieve a controlled, systemic reduction of a potent male hormone metabolite called Dihydrotestosterone (DHT). The medication achieves this through a high-level mechanism of targeted enzyme blockade. By competitively and specifically inhibiting the 5-alpha reductase enzyme, Finasteride effectively blocks the conversion of the primary male hormone Testosterone into the more active metabolite, DHT. This inhibition results in a significant decrease in serum and tissue DHT concentrations. The final effect is the suppression of androgen activity in specific, highly responsive tissues, establishing its role as a precise androgen modulator.

Regulatory References

  1. Finasteride Mechanism of Action (NIH)

What side effects are possible with Finta?

The safety profile of Finta (Finasteride) is defined by officially documented adverse reactions classified by frequency and the physiological systems affected, based on regulatory data.

Frequency-Classified Adverse Reactions

The most frequent effects are documented in the Reproductive system and breast disorders category. Common reactions (occurring in 1% to 10% of patients) include decreased libido, erectile dysfunction, and ejaculation disorder. Uncommon reactions (0.1% to 1%) include depressed mood, skin rash, breast tenderness and/or enlargement (gynaecomastia), and testicular pain. Hypersensitivity reactions (such as swelling of the face and lips) are classified as Rare.

Serious Safety Considerations

Official regulatory documents note a specific warning regarding the increased risk of high-grade prostate cancer in some men taking this class of medication, which requires careful interpretation of Prostate Specific Antigen (PSA) levels. Cases of male breast cancer have been reported during post-marketing surveillance; the frequency is classified as Not Known.

Time-Related Patterns and Constraints

The label indicates that certain sexual side effects are often more common at the start of therapy. Additionally, the FDA and other government agencies have documented reports of these effects persisting after the discontinuation of the medication in some individuals. The medication is contraindicated in women who are or may become pregnant due to the potential risk to a male fetus, and caution is advised for patients with hepatic impairment (liver problems) as the effects have not been fully studied in this population.

Overdose and Emergency Response

Overdose and when to seek help

Entity Official Regulatory Statement
Documented overdose presentations No dose-related undesirable effects were observed following administration of Finasteride in clinical trials.
Physiological systems affected No specific physiological systems are documented as being affected by acute overdosage, as toxic effects were not reported in high-dose studies.
Dose-related or exposure-related factors Single doses up to 400 mg and multiple daily doses up to 80 mg/day administered for three months were studied without resulting in dose-related undesirable effects.
Emergency-response statements No specific treatment of overdosage with Finasteride is officially recommended in regulatory documents.

Overdose Classifications (High-Level)

Classification Entity Official Regulatory Statement
Severity classification Not specifically classified or detailed due to the reported absence of dose-related undesirable effects in clinical investigations.
Overdose-context constraints Procedural instructions for overdosage are limited to the general expectation of symptomatic and supportive treatment; no specific procedural steps are explicitly mandated in regulatory documents.

Resulting Overdose Structure

Official overdose statements:

  • No specific antidote is known or prescribed for Finasteride overdosage according to prescribing information.
  • Clinical trials involving high single and multiple exposures did not result in a specific toxic syndrome or dose-related undesirable effects.
  • The official labeling does not detail any population-specific overdose notes or specialized monitoring requirements for this scenario.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by the lack of observed acute toxicity, stating that no dose-related undesirable effects were reported even at exposures significantly exceeding normal use levels. This clinical finding results in the official regulatory position that no specific treatment is recommended, structuring any required intervention as general symptomatic and supportive care.

Therapeutic Uses of Finta

What Finta Treats: Main Uses and Benefits

Finta (Finasteride) is relevant for the long-term management of certain chronic conditions that affect adult males, specifically within the therapeutic domains of Benign Prostatic Hyperplasia (BPH) and Male Pattern Hair Loss. This medication is used within these contexts to manage symptoms and support long-term stability.

It is applied to address symptom clusters related to Lower Urinary Tract Distress (urinary frequency, weak stream, nocturia) linked to an enlarged prostate, and it is relevant for managing the progressive nature of hair loss that leads to gradual hair thinning and recession in susceptible adult males. This medication contributes to slowing the rate of further hair loss and may assist in managing hair density.

“The role of this therapy supports an easing of the overall symptom burden and contributes to improved day-to-day comfort.”

The role of this therapy supports an easing of the overall symptom burden, contributes to improved comfort, and may assist with providing symptomatic support against potential urinary complications.

Quick Fact: Relief for Chronic Symptoms
Finta is commonly used to help manage two specific, chronic symptomatic conditions in adult males: prostate enlargement and hereditary pattern balding.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Finta is strictly approved for use in Adult Males only. Its official regulatory labeling establishes clear boundaries for use based on gender, age, reproductive status, and specific medical conditions. Use is not indicated for women or children under the age of 18, as safety and efficacy have not been formally established in these populations by regulatory agencies.

Official Eligibility Status

Category Regulatory Status
Contraindicated Females who are or may be pregnant; Known hypersensitivity to the drug or any of its components.
Not Indicated Women generally; Pediatric patients (under 18 years of age).

The most critical restriction is the absolute contraindication in pregnant females, which is due to the potential risk of causing external genital abnormalities in a developing male fetus. For this reason, women who are pregnant or who may become pregnant must also not handle crushed or broken tablets. For eligible adult males, use requires caution and monitoring in the presence of liver function abnormalities (hepatic impairment), as the drug is extensively metabolized by the liver. Use in older adults and patients with renal insufficiency typically requires no specific dosage adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation on Finta (Finasteride) indicates a profile with no clinically significant drug-drug interactions identified in standard studies. Clinical testing with commonly co-administered therapies such as Antipyrine, Digoxin, Propranolol, Theophylline, and Warfarin found no clinically meaningful interactions. Finta does not appear to significantly affect the Cytochrome P450-linked enzyme system responsible for metabolizing other medicines.


Potential Metabolic and Product Considerations

While direct interactions are absent, regulators acknowledge potential pharmacokinetic changes due to Finasteride's primary metabolic pathway. The medication is metabolized by the CYP3A4 enzyme, making it probable that co-administration with strong CYP3A4 inhibitors or inducers may alter Finasteride plasma concentrations.


Category Documented Constraint
Food/Meals Administration is permitted with or without meals (no timing constraint).
Herbal Products Co-administration with the herbal product St John's wort (Hypericum perforatum) is noted as potentially reducing the medication's effect.
Hepatic Function Caution is advised in patients with liver function abnormalities due to the extensive hepatic metabolism of the drug.

No mandatory timing or separation requirements are documented for co-administration with other prescription medicines.

Mechanism of Action

Molecular Mechanism: Targeted Enzyme Inhibition

This section explains the core molecular action: Finta functions as a highly specific, competitive inhibitor of the 5-alpha reductase enzyme , predominantly blocking the sensitive Type 2 isoform. This immediate blockade prevents the enzyme from catalyzing the conversion reaction in the pathway, which initiates the downstream biochemical sequence.

Pathway Effect: Modulating Androgen Metabolism

The inhibition directly intervenes in the Androgen Metabolism Pathway by preventing the conversion of Testosterone into the significantly more potent metabolite, Dihydrotestosterone (DHT). This molecular intervention leads to a controlled, pronounced decrease in the concentration of DHT in both systemic circulation and targeted tissues.

Physiological Outcome: Diminished Androgenic Signal

The resulting dramatic reduction in DHT modifies the Androgen Receptor occupancy and subsequent signal transduction in specific cells. This functional change creates a state of diminished androgenic signal in specific androgen-dependent cellular processes, which represents the final physiological consequence of the enzyme blockade.

Dosage and Administration Information

Instruction Map: How to use Finta — Administration Guidelines

This map consolidates the instructions for the administration and dosing of Finta (Finasteride).

Administration scope Instruction
Route of administration The medication is designed for oral administration as a film-coated tablet.
Dosing schedule For Benign Prostatic Hyperplasia (BPH), the standard dose is one 5 mg tablet taken once daily. For Male Pattern Hair Loss, the standard dose is one 1 mg tablet taken once daily.
Timing in relation to meals (if applicable) The tablet may be administered with or without food.
Preparation requirements (if applicable) The film-coated tablet must be swallowed whole; it should not be crushed, broken, or chewed.
Age-group administration rules The medication is not indicated for use in children or adolescents. No dosage adjustment is necessary for older adults.
Missed-dose rules If a dose is missed, it should be skipped. The patient should then resume the regular once-daily schedule and not take a double dose to compensate.
Special procedural conditions No dose adjustment is required for adult patients with varying degrees of renal impairment.

Instruction classifications (high-level)

Classification Detail
Administration method type Oral ingestion.
Frequency pattern Daily (once per day).
Use-context constraints Continuous, long-term use is necessary to maintain the therapeutic effect. Assessment of benefit may require at least three to six months of daily administration.

Resulting procedural structure

Step sequence:

  • Take the prescribed tablet strength (1 mg or 5 mg) once daily.
  • Swallowing the tablet whole is required for proper administration.
  • Take the dose with or without food to maintain consistency.
  • In the event of a missed dose, resume the routine schedule the next day without doubling the dose.

Connection to the overall use protocol: The administration protocol requires a precise, once-daily oral intake of the designated tablet strength to ensure consistent systemic levels. This strict adherence to frequency and the long-term duration of treatment are key components for maintaining the standardized use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Finta


Evidence for Use in Symptomatic Prostate Enlargement (BPH)

The research exploring Finasteride for symptomatic prostate enlargement is largely based on multi-year, controlled trials and long-term observational studies. These studies focused on adult men diagnosed with BPH and were used in research exploring how symptoms change over time. Primary research examined outcomes related to physical discomfort and daily functioning, such as changes in the International Prostate Symptom Score (IPSS), which measures the severity of urinary issues. Studies also monitored objective measures, including maximal urinary flow rate and the measurement of prostate volume, which is relevant in evidence describing how symptoms are measured.

What remains unclear is the immediate or short-term impact, as the time required to document the measured outcomes often spanned many months. Furthermore, there is limited information for long-term outcomes after the study medicine is stopped.


Evidence for Use in Male Pattern Hair Loss

Research concerning Finasteride for male pattern hair loss primarily involved randomized, double-blind, placebo-controlled clinical trials, initially over a short-term period, along with longer-term extension studies. These studies focused on men who had mild to moderate hair thinning, mainly on the top and mid-scalp areas. Research examined how hair density, specifically the Target Area Hair Count (TAHC), was measured over defined time intervals. Studies also monitored changes using standardized photographic assessments and assessments by investigators.

Studies monitored how symptoms evolved in the observed populations over periods of one to five years. Research describes that studies monitored TAHC measurements in the groups receiving the study drug and those receiving placebo, with these findings occurring gradually over the months the subjects were observed. Photographic findings also indicated patterns related to the measured visual appearance of the hair in the vertex and mid-scalp areas.


Understanding Key Research Limitations and Evidence Gaps

For both BPH and hair loss, patterns observed in the long-term evidence required continuous administration to be maintained. Research so far indicates that the measured outcomes were not sustained after the medicine was stopped. The available evidence is limited for men with advanced hair loss or those focused on changes solely to the frontal hairline. Long-term outcomes following a decade or more of use are not fully established, as follow-up durations were limited in the earliest controlled trials.

Key Studies & References Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group

Frequently Asked Questions (FAQ)

Common questions about Finta (FAQ)

Q: What is the main reason Finta is prescribed?

A: According to official regulatory documents, Finta is indicated for two main uses in men: treating symptoms of benign prostatic hyperplasia (BPH, or enlarged prostate) and addressing male pattern hair loss (androgenetic alopecia). The specific dose prescribed depends on the condition being treated.

Q: What is the typical timeframe before Finta starts working?

A: Studies indicate that the effects of Finta occur gradually. For symptomatic prostate enlargement, the full benefit may take up to six months of continuous daily use. For male pattern hair loss, measurable improvement is typically observed after three to six months.

Q: Do most people experience side effects when taking Finta?

A: Based on clinical trials and post-marketing data, most people do not experience serious side effects when using Finta. The commonly discussed sexual side effects, such as decreased libido or erectile dysfunction, occur in a small percentage of patients and are generally classified as uncommon.

Q: Are there any common over-the-counter medicines that interact with Finta?

A: Regulatory documents indicate that Finta is generally well-tolerated, and standard studies have not identified clinically significant interactions with most other drugs. This general finding extends to the use of many common over-the-counter medicines.

Q: Does Finta require any special monitoring or lab tests?

A: Official safety guidance indicates that certain blood and urine tests are sometimes referenced during use to monitor for unwanted effects. Finta is known to affect the results of the Prostate Specific Antigen (PSA) test, which is referenced in official documents as requiring careful interpretation by a healthcare provider.

Q: Does Finta interact with herbal supplements?

A: While studies have not identified many significant interactions, official information emphasizes consulting a healthcare provider regarding the use of herbal supplements. This is because some herbal products may potentially alter the drug's effect in the body.

Q: Is Finta used to treat other conditions besides the main one?

A: Official regulatory approval is limited to only two conditions: symptomatic benign prostatic hyperplasia (BPH) and male pattern hair loss. Finta is not approved or indicated for the prevention of prostate cancer, despite related research findings.

Q: Can Finta affect fertility in men or women?

A: The drug is contraindicated in pregnant women due to the risk of causing harm to a developing male fetus. Official reports also indicate that some men using finasteride have reported concerns related to male fertility, including the ability to have children.

Q: What are the signs of an allergic reaction to Finta?

A: Signs of a hypersensitivity reaction (allergic reaction) are categorized as rare. Less common signs that have been reported include hives, itching, or skin rash, as well as swelling of the lips, face, arms, hands, lower legs, or feet.

Q: Are there any known long-term effects from Finta?

A: The official product information indicates that Finta is intended for long-term administration. However, official safety surveillance notes rare reports of male breast cancer. Furthermore, some sexual side effects have been reported to persist in some individuals even after they have discontinued the medication.

Q: Is Finta known to cause weight gain or loss?

A: Official safety information indicates that unusual weight gain or loss has been reported as a less common side effect. It is important to note that rapid weight gain is also mentioned in connection with use of the medication.

Q: Can Finta affect sleep patterns?

A: While not a common effect listed in initial trials, some reports have included insomnia (difficulty sleeping) during post-marketing surveillance. This type of symptom has also been noted in connection with reports of persistent side effects after discontinuing the medicine.

Q: Is it okay to have coffee or tea while taking Finta?

A: Official documents on product use indicate that you can generally eat and drink normally while taking Finta. There are typically no specific restrictions documented regarding the intake of coffee, tea, or other caffeinated beverages.

Q: How long does Finta stay in the body after the last dose?

A: The chemical substance has a relatively short half-life, meaning the medication itself may take a few days to be cleared from the body. However, the drug's key therapeutic effect, the suppression of the DHT hormone, has been observed to return to normal levels within about two weeks after a person stops administration.

Q: Can Finta cause issues with concentration or focus?

A: Reports from some users have included cognitive symptoms such as trouble concentrating or feeling like they have 'brain fog.' While this has been noted in post-marketing reports, formal clinical studies on a causal link between Finta and cognitive impairment remain limited.

Q: Is Finta considered a new medication?

A: No, Finta is not considered a new medication. Official regulatory history shows that the 5 mg strength received its initial approval from the FDA in 1992, with the 1 mg strength approved later in 1997.

Q: What is the risk of dependence or withdrawal with Finta?

A: Official regulatory reporting includes observations of a collection of persistent side effects after men have stopped using the medication. These persistent symptoms, which can include sexual and neurological effects, are sometimes referred to as post-finasteride syndrome (PFS).

Q: What happens if Finta is taken with alcohol?

A: Official guidance indicates that you can consume alcohol while taking Finta. However, some regulatory sources mention that heavy alcohol use may potentially affect the drug’s protective effect against low-grade prostate cancer.

Q: Does Finta have restrictions on driving or operating machinery?

A: According to official product guidance, Finta is not known to impair your ability to drive, cycle, or operate machinery. It is generally not associated with effects that would cause restrictions in these areas.

Q: Can taking Finta impact the effectiveness of birth control pills?

A: Official sources indicate that Finasteride is not thought to stop or reduce the effectiveness of any type of contraception, including birth control pills.

Q: Does Finta need to be taken at a specific time of day?

A: Official administration instructions state that it does not matter what time of day you take Finta. The most important factor is consistency; the dose is intended for once-daily administration at approximately the same time each day.

Q: Are there guidelines for what to do if a minor side effect occurs?

A: Official guidelines recommend informing a healthcare provider if side effects are noticed. This allows them to monitor progress and check whether any adjustments, such as a dosage change or further monitoring, may be appropriate.

Q: What does 'contraindication' mean in relation to Finta?

A: In regulatory terms, a contraindication means that the medication must not be used in certain specific situations or patient groups due to a significant risk of harm. The most critical example for Finta is its absolute contraindication in pregnant women because of the potential risk to a developing male fetus.

How should Finta be stored and disposed of?

The storage and disposal of Finta (Finasteride) tablets are strictly governed by regulatory requirements to ensure product stability and safety.

Storage Requirements

Finta must be stored in the original container, kept tightly closed, and held at a temperature not exceeding 30 C (86 F). The product must be protected from excess heat, moisture, and direct light. To maintain child safety, the medicine must be stored out of the sight and reach of children.

Special Handling and Disposal

Pregnant women, or those who may become pregnant, must not handle crushed or broken tablets due to the potential for absorption. The official disposal rule is to not throw away unused or expired medicine via household waste or wastewater. Instead, the product should be disposed of by returning it to a pharmacy or following instructions for an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Finta found in:

A-Z Index: